MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:42Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Alpha-1 blockers]]
			[[Category:BPH treatments]]
			[[Category:Antihypertensives]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #217

2026-05-23T04:15:06Z

parser-claude batch MedTemplate pre-fill, Top 300 #217

New page

{{MedTemplate
| generic = Terazosin
| brand = Hytrin (US brand discontinued); mostly generic
| structure =
| classes = [[:Category:Alpha-1_blockers|Alpha-1 adrenergic blocker (non-selective)]], [[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]], [[:Category:Antihypertensives|Antihypertensive]]
| uses = <vote slug="bph-luts-use">Benign prostatic hyperplasia (LUTS)</vote>, <vote slug="hypertension-fourth-line-use">Hypertension (later-line)</vote>
| starting_dose = 1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg
| preparations = 1, 2, 5, 10 mg capsules and tablets
| fda_max = 20 mg/d
| pill_id =
| routes = Oral
| onset = BP and symptomatic LUTS improvement within 1-2 weeks
| duration = 24 hours
| halflife = ~12 hours<ref name="hytrin-label">FDA Prescribing Information, terazosin HCl, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019057s032lbl.pdf</ref>
| bioavailability = >90% (oral; not significantly affected by food)<ref name="hytrin-label" />
| pregnancy = Limited data.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="terazosin-mech-claim">Terazosin is a non-selective α1 adrenergic receptor antagonist that relaxes vascular smooth muscle (lowering BP) and prostatic/bladder-neck smooth muscle (improving urodynamic flow); like doxazosin, it lacks α1A subtype selectivity, producing more peripheral hypotension than tamsulosin and the characteristic '''first-dose syncope''' that drives bedtime initiation.</vote> Intraoperative floppy iris syndrome is a recognized class effect. Recently emerging evidence (observational) suggests possible Parkinson's disease risk reduction via PGK1 binding — investigational and not a clinical indication<ref name="hytrin-label" />.
}}

== References ==
<references />

Terazosin - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #217